Keratoacanthoma versus Squamous-Cell Carcinoma: Histopathological Features and Molecular Markers.

IF 1.6 Q3 DERMATOLOGY Dermatopathology Pub Date : 2024-10-08 DOI:10.3390/dermatopathology11040029
Hisham F Bahmad, Kalin Stoyanov, Teresita Mendez, Sally Trinh, Kristy Terp, Linda Qian, John Alexis
{"title":"Keratoacanthoma versus Squamous-Cell Carcinoma: Histopathological Features and Molecular Markers.","authors":"Hisham F Bahmad, Kalin Stoyanov, Teresita Mendez, Sally Trinh, Kristy Terp, Linda Qian, John Alexis","doi":"10.3390/dermatopathology11040029","DOIUrl":null,"url":null,"abstract":"<p><p>Considerable controversy exists within the field of dermatopathology in differentiating keratoacanthoma (KA) from squamous-cell carcinoma (SCC). KAs are rapidly growing, benign squamous tumors that are typically well differentiated. This controversy stems from the diverging perspectives on the management, classification, and diagnosis of each entity. Many believe that KAs are benign neoplasms in which intervention may be unnecessary since they are self-limiting and resolve on their own. On the other hand, SCC needs to be treated, as it carries significant morbidity and mortality risks. Early diagnosis and treatment are vital to prevent serious consequences of SCC. Nevertheless, KAs may resemble SCC grossly and microscopically. Various ancillary tests, including immunohistochemical (IHC) staining, have been proposed to differentiate between these entities, though mixed patterns of expression can limit the diagnostic utility of these techniques. Research into this topic is ongoing, with newer genetic and molecular findings illuminating the previously difficult-to-understand aspects of KA and increasing our understanding of this entity. In this review, KA and SCC will be compared along the lines of histological features, genetic, immune, and molecular markers, differential diagnosis, and management to clarify the similarities, differences, and misconceptions about both entities.</p>","PeriodicalId":42885,"journal":{"name":"Dermatopathology","volume":"11 4","pages":"272-285"},"PeriodicalIF":1.6000,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11503433/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatopathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/dermatopathology11040029","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Considerable controversy exists within the field of dermatopathology in differentiating keratoacanthoma (KA) from squamous-cell carcinoma (SCC). KAs are rapidly growing, benign squamous tumors that are typically well differentiated. This controversy stems from the diverging perspectives on the management, classification, and diagnosis of each entity. Many believe that KAs are benign neoplasms in which intervention may be unnecessary since they are self-limiting and resolve on their own. On the other hand, SCC needs to be treated, as it carries significant morbidity and mortality risks. Early diagnosis and treatment are vital to prevent serious consequences of SCC. Nevertheless, KAs may resemble SCC grossly and microscopically. Various ancillary tests, including immunohistochemical (IHC) staining, have been proposed to differentiate between these entities, though mixed patterns of expression can limit the diagnostic utility of these techniques. Research into this topic is ongoing, with newer genetic and molecular findings illuminating the previously difficult-to-understand aspects of KA and increasing our understanding of this entity. In this review, KA and SCC will be compared along the lines of histological features, genetic, immune, and molecular markers, differential diagnosis, and management to clarify the similarities, differences, and misconceptions about both entities.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
角化棘皮瘤与鳞状细胞癌:组织病理学特征与分子标记。
皮肤病理学领域在区分角化棘皮瘤(KA)和鳞状细胞癌(SCC)方面存在很大争议。角化棘皮瘤是一种生长迅速的良性鳞状肿瘤,通常分化良好。这种争议源于对每种实体的管理、分类和诊断的不同观点。许多人认为,KAs 是良性肿瘤,由于具有自限性并能自行消退,因此可能不需要干预。另一方面,SCC 则需要治疗,因为它有很大的发病率和死亡率风险。早期诊断和治疗对预防 SCC 的严重后果至关重要。尽管如此,KA 可能在大体和显微镜下与 SCC 相似。人们提出了包括免疫组化(IHC)染色在内的各种辅助检测方法来区分这些实体,但混合表达模式可能会限制这些技术的诊断效用。对这一主题的研究仍在继续,最新的遗传和分子研究结果揭示了 KA 以前难以理解的方面,加深了我们对这一实体的了解。在这篇综述中,我们将从组织学特征、遗传、免疫和分子标记、鉴别诊断和管理等方面对 KA 和 SCC 进行比较,以澄清两者的异同和误解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Dermatopathology
Dermatopathology DERMATOLOGY-
自引率
5.30%
发文量
39
审稿时长
11 weeks
期刊最新文献
Expression of TRPS1 in Metastatic Tumors of the Skin: An Immunohistochemical Study of 72 Cases. Undifferentiated Pleomorphic Sarcoma with Reactive Eccrine Syringofibroadenoma: A Case Report. Keratoacanthoma versus Squamous-Cell Carcinoma: Histopathological Features and Molecular Markers. Ethical Issues Regarding Dermatopathology Care for Service-Members: A Review. Enhancing Melanoma Diagnosis with Advanced Deep Learning Models Focusing on Vision Transformer, Swin Transformer, and ConvNeXt.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1